Healthcare / BiotechnologyWarsaw
$2.80
-0.03 (-1.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-16.2M · quality 57.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$212M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-16.0%
↓Gross Margin
56.1%
↑Debt/Equity
0.68
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.9%
FCF CAGR
—
FCF margin
-38.6%
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $42.0M · net income $-19.9M · FCF $-16.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $42.0M | $42.0M | $71.8M | $58.6M | $50.4M |
| Net Income | $-19.9M | $-19.9M | $7.5M | $4.8M | $6.1M |
| EBITDA | $-19.3M | $-19.3M | $12.7M | $9.1M | $16.2M |
| EPS | -0.26 | -0.26 | 0.11 | 0.07 | 0.09 |
| Gross Margin | 56.1% | 56.1% | 61.7% | 60.0% | 55.4% |
| Operating Margin | -31.1% | -31.1% | 17.4% | 14.8% | 18.4% |
| Net Margin | -47.4% | -47.4% | 10.5% | 8.1% | 12.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.68 | 0.68 | 0.66 | 0.62 | 0.14 |
| Current Ratio | 0.90 | 0.90 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-16.2M | $-16.2M | $-27.0M | $-5.3M | $-33.8M |
| Returns | |||||
| ROE | -16.0% | -16.0% | 6.2% | 4.2% | 5.8% |
| Valuation | |||||
| P/E | — | — | 40.64 | 65.51 | 69.82 |
| EV/EBITDA | — | — | 31.06 | 41.59 | 24.66 |
| P/B | 1.63 | 1.63 | 2.60 | 2.77 | 3.89 |
| Growth & Yield | |||||
| Revenue Growth | -41.5% | -41.5% | 22.4% | 16.3% | — |
| EPS Growth | -336.4% | -336.4% | 63.0% | -25.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-48.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.11 → -0.26
Residual
-48.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.